RxDoctor Payments Data

Mauro Ruffy, MD

Otolaryngology/Facial Plastic Surgery · San Jose, CANPI 1376725630

Payments from drug & device makers

What this record shows

11 manufacturers reported payments, led by Aerin Medical Inc. at 43.5% of the total. Reporting peaked in 2021 at $1,900 and has fallen 79.9% since, to $382 in 2025.

$4,279in general payments, 2019–2025

Across 47 payments — averaging $91.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Aerin Medical Inc.$2K
  • Stryker$1K
  • Medtronic$310
  • Optinose US, Inc.$267
  • Spirair, Inc.$186
  • Baxter Healthcare$95
  • plus $203 from 5 others
$120,079in ownership & investment interests, 2019–2025

Across 1 payment — averaging $120,079 each. An ownership or investment interest held by the physician or an immediate family member.

  • Spirair, Inc.$120K

What the payments were for

  • Travel & lodging$2,12850%
  • Food & beverage$2,15150%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,279 in reported general payments places this provider in the 75th percentile of 102 otolaryngology/facial plastic surgery providers in California.

See all otolaryngology/facial plastic surgery providers in California

Medicare billing

Part B allowed, 2024
$123,819
Medicare patients
265
Services billed
882

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Ipratropium Bromide129$3,093
Azelastine Hcl87$2,278
Omeprazole46$1,016
Fluticasone Propionate53$817
Mometasone Furoate17$228
Pantoprazole Sodium11$158
Sumatriptan Succinate18$153
Cephalexin11$46

Paid to pharmacies, not to this prescriber.

Other otolaryngology/facial plastic surgery in San Jose

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →